Methotrexate-Induced Accelerated Nodulosis: A Case Series

Area of Science:

• Rheumatology
• Dermatology
• Immunology

Background:

• Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD) for various autoimmune conditions.
• Methotrexate-induced accelerated nodulosis (MIAN) is an uncommon adverse effect associated with MTX treatment.
• MIAN can cause significant morbidity and impact treatment adherence in patients with autoimmune diseases.

Purpose of the Study:

• To describe the clinical characteristics, diagnostic methods, and management of patients experiencing MIAN.
• To enhance the medical community's awareness of this rare MTX side effect.
• To provide insights for earlier diagnosis and improved clinical strategies for MIAN.

Main Methods:

• A case series approach was employed.
• Patients diagnosed with MIAN were retrospectively reviewed.
• Clinical data, including presentation, diagnosis, and treatment outcomes, were analyzed.

Main Results:

• The study presents a series of patients with MIAN, detailing their specific clinical presentations.
• Diagnostic challenges and successful management strategies are discussed based on the cases.
• The findings highlight the variability in MIAN presentation and response to interventions.

Conclusions:

• Increased recognition of MIAN is crucial for timely diagnosis and intervention.
• Effective management strategies can mitigate the impact of this rare MTX complication.
• This case series contributes to understanding and managing methotrexate-induced accelerated nodulosis.